DMD is a pediatric rare disease that affects approximately 1 in 3,600 boys worldwide. It is caused by a genetic mutation that renders boys unable to make functional dystrophin, a protein critical for normal muscle function. Young men with the disease show progressive signs of physical impairment as early as age three, lose the ability to walk in their teens, and die of cardiac or respiratory failure in their late twenties or early thirties.
About DART Therapeutics DART Therapeutics Inc., Cambridge, Mass., is a biotechnology firm applying a new model for drug development to rare pediatric neuromuscular diseases. In the DART model, patient foundations join with biotechnology industry veterans to impact a central problem in rare diseases: Rapid therapy development. DART is focused on Duchenne muscular dystrophy, a fatal neuromuscular disease for which there is no effective treatment. For more information, please visit www.dartrx.com.
Media Contact: Shanti Skiffington 617.921.0808 shanti.skiffington(at)gmail.com
SOURCE DART Therapeutics Inc.